Synovial Sarcoma – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Synovial Sarcoma – Pipeline Review, H1 2017’, provides an overview of the Synovial Sarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Synovial Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Synovial Sarcoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Synovial Sarcoma

– The report reviews pipeline therapeutics for Synovial Sarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Synovial Sarcoma therapeutics and enlists all their major and minor projects

– The report assesses Synovial Sarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Synovial Sarcoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Synovial Sarcoma

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Synovial Sarcoma pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adaptimmune Therapeutics Plc

Advenchen Laboratories LLC

EpiZyme Inc

Immune Design Corp

Immunocore Ltd

Johnson & Johnson

Karyopharm Therapeutics Inc

Merck & Co Inc

Novartis AG

OncoTherapy Science Inc

Pfizer Inc

Takara Bio Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Synovial Sarcoma Overview

Synovial Sarcoma Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Synovial Sarcoma Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Synovial Sarcoma Companies Involved in Therapeutics Development

Adaptimmune Therapeutics Plc

Advenchen Laboratories LLC

EpiZyme Inc

Immune Design Corp

Immunocore Ltd

Johnson & Johnson

Karyopharm Therapeutics Inc

Merck & Co Inc

Novartis AG

OncoTherapy Science Inc

Pfizer Inc

Takara Bio Inc

Synovial Sarcoma Drug Profiles

ACXT-3102 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AL-3818 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

axitinib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CMB-305 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CUE-102 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

everolimus Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-3377794 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OTSA-101 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pembrolizumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

quisinostat hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

selinexor Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SSTC-104 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tazemetostat Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TBI-1301 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synovial Sarcoma Dormant Projects

Synovial Sarcoma Discontinued Products

Synovial Sarcoma Product Development Milestones

Featured News & Press Releases

Feb 22, 2016: The completion of phase I clinical study of the anti-cancer therapeutic antibody ‘OTSA101’ against synovial sarcoma

Jul 30, 2012: OncoTherapy Science Receives Patent For OTSA101 In Japan And US

Oct 16, 2011: OncoTherapy Science's Subsidiary Receives French Approval For Clinical Trial Of OTSA101

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Synovial Sarcoma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Synovial Sarcoma Pipeline by Adaptimmune Therapeutics Plc, H1 2017

Synovial Sarcoma Pipeline by Advenchen Laboratories LLC, H1 2017

Synovial Sarcoma Pipeline by EpiZyme Inc, H1 2017

Synovial Sarcoma Pipeline by Immune Design Corp, H1 2017

Synovial Sarcoma Pipeline by Immunocore Ltd, H1 2017

Synovial Sarcoma Pipeline by Johnson & Johnson, H1 2017

Synovial Sarcoma Pipeline by Karyopharm Therapeutics Inc, H1 2017

Synovial Sarcoma Pipeline by Merck & Co Inc, H1 2017

Synovial Sarcoma Pipeline by Novartis AG, H1 2017

Synovial Sarcoma Pipeline by OncoTherapy Science Inc, H1 2017

Synovial Sarcoma Pipeline by Pfizer Inc, H1 2017

Synovial Sarcoma Pipeline by Takara Bio Inc, H1 2017

Synovial Sarcoma Dormant Projects, H1 2017

Synovial Sarcoma Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Synovial Sarcoma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports